Four Corners Physical Therapy Limited Partnership | |
3832 E Main St, Units E & F, Farmington, NM 87402-8749 | |
(505) 564-2955 | |
(505) 564-2662 |
Full Name | Four Corners Physical Therapy Limited Partnership |
---|---|
Type | Facility |
Speciality | Clinic/center - Physical Therapy |
Location | 3832 E Main St, Farmington, New Mexico |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073534194 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Four Corners Physical Therapy Limited Partnership 1300 W Sam Houston Pkwy S, Suite 300, Houston, TX 77042-2447 Ph: (713) 297-7000 | Four Corners Physical Therapy Limited Partnership 3832 E Main St, Units E & F, Farmington, NM 87402-8749 Ph: (505) 564-2955 |
News Archive
California Gov. Arnold Schwarzenegger unveiled his latest spending plan for the financially strapped state on Friday, and news coverage focused on the deep cuts he is proposing.
According to a report released by the University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health, flu vaccination rates among young children and high-risk adults are much lower than expected across the country, leaving millions of Americans unprotected should a major flu outbreak occur.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
› Verified 5 days ago